SGLT2 Inhibitors Cut Heart Failure Hospitalizations While Empagliflozin May Reduce Arrhythmia Risk
A network meta-analysis of 32 RCTs finds SGLT2 inhibitors consistently reduce hospitalization for heart failure, with empagliflozin showing a signal for lower ventricular arrhythmia risk.
Summary
Researchers pooled data from 32 randomized controlled trials involving over 140,000 patients to compare how SGLT2 inhibitors and GLP-1 receptor agonists affect heart rhythm and cardiovascular outcomes in people with type 2 diabetes or heart failure. SGLT2 inhibitors — including dapagliflozin and empagliflozin — consistently reduced hospitalizations for heart failure. Empagliflozin also showed a statistically significant but exploratory signal for lower ventricular arrhythmia risk in diabetic patients. Dapagliflozin and empagliflozin reduced cardiovascular and all-cause mortality in relevant subgroups. Most drugs did not increase arrhythmia risk. Safety signals around diabetic ketoacidosis and fractures require cautious interpretation due to inconsistent adverse-event reporting across trials.
Detailed Summary
Heart failure and type 2 diabetes remain two of the most burdensome conditions in cardiovascular medicine, and the drugs used to treat them — SGLT2 inhibitors and GLP-1 receptor agonists — have reshaped outcomes over the past decade. Yet their specific effects on ventricular arrhythmias, a leading cause of sudden cardiac death, have remained poorly understood. This network meta-analysis set out to fill that gap.
Researchers systematically searched four major databases through May 2026, identifying 37 publications from 32 independent randomized controlled trials enrolling 140,156 participants. The analysis evaluated nine outcomes, including ventricular arrhythmias, cardiovascular mortality, all-cause mortality, and hospitalization for heart failure across two disease networks: type 2 diabetes and heart failure.
The headline finding is that SGLT2 inhibitors consistently reduced hospitalization for heart failure across both disease networks. Empagliflozin showed a statistically significant but exploratory reduction in ventricular arrhythmia risk in the type 2 diabetes network (OR 0.31, 95% CI 0.11–0.86). Dapagliflozin reduced cardiovascular and all-cause mortality in the heart failure network, while empagliflozin and liraglutide did so in the type 2 diabetes network. Dapagliflozin was also associated with lower acute kidney injury risk. Most drugs did not significantly increase arrhythmia risk.
These findings carry meaningful clinical implications. For patients managing both diabetes and heart disease, SGLT2 inhibitors appear to offer broad cardiovascular protection, and empagliflozin's arrhythmia signal — if confirmed — could influence prescribing decisions in high-risk patients prone to sudden cardiac events.
However, important caveats apply. The evidence networks were largely placebo-centered with few closed loops, making head-to-head drug comparisons reliant on the transitivity assumption. Adverse-event reporting was non-uniform across trials, limiting interpretation of safety signals for diabetic ketoacidosis, fractures, and hypoglycemia. Arrhythmia outcomes were not prespecified or adjudicated in most trials. The summary is based on the abstract only.
Key Findings
- SGLT2 inhibitors consistently reduced hospitalization for heart failure across type 2 diabetes and heart failure patient populations.
- Empagliflozin showed an exploratory signal for 69% lower ventricular arrhythmia risk in type 2 diabetes patients (OR 0.31).
- Dapagliflozin reduced cardiovascular and all-cause mortality in heart failure patients; empagliflozin and liraglutide did so in type 2 diabetes patients.
- Dapagliflozin was associated with lower acute kidney injury risk; albiglutide and liraglutide with lower hypoglycemia risk.
- No significant increase in diabetic ketoacidosis risk was detected for empagliflozin; semaglutide fracture signal needs cautious interpretation.
Methodology
This is a disease-stratified network meta-analysis of 32 independent RCTs enrolling 140,156 participants with type 2 diabetes and/or heart failure, drawn from four databases searched through May 2026. Nine cardiovascular and safety outcomes were evaluated across two separate disease networks. Treatment rankings used P-scores but were constrained by largely placebo-centered networks with limited closed loops.
Study Limitations
The evidence networks were largely placebo-centered with few closed loops, making drug-to-drug comparisons dependent on the unverifiable transitivity assumption; P-score rankings should be treated as exploratory, not comparative. Adverse-event reporting was inconsistent across trials, limiting reliability of safety conclusions for diabetic ketoacidosis, fractures, and arrhythmias. Ventricular arrhythmia outcomes were not prespecified or adjudicated in most trials, reducing confidence in arrhythmia-specific findings. Summary is based on the abstract only.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: